NCT00064038View on ClinicalTrials.gov

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

PHASE3CompletedINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

May 31, 2012

Conditions

Multiple MyelomaPlasma Cell Neoplasm

Interventions

DRUG

dexamethasone

Given orally

DRUG

lenalidomide

Given orally

OTHER

placebo

Given orally

Trial Locations (2)

48073

William Beaumont Hospital - Royal Oak Campus, Royal Oak

84106

Utah Cancer Specialists at UCS Cancer Center, Salt Lake City

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK

NCT00064038 - S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | Biotech Hunter | Biotech Hunter